Search Results - "Jens, Huober"

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer by Goetz, Matthew P, Toi, Masakazu, Campone, Mario, Sohn, Joohyuk, Paluch-Shimon, Shani, Huober, Jens, Park, In Hae, Trédan, Olivier, Chen, Shin-Cheh, Manso, Luis, Freedman, Orit C, Garnica Jaliffe, Georgina, Forrester, Tammy, Frenzel, Martin, Barriga, Susana, Smith, Ian C, Bourayou, Nawel, Di Leo, Angelo

“…Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with…”
Get full text

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial by Riethdorf, Sabine, Müller, Volkmar, Loibl, Sibylle, Nekljudova, Valentina, Weber, Karsten, Huober, Jens, Fehm, Tanja, Schrader, Iris, Hilfrich, Jörn, Holms, Frank, Tesch, Hans, Schem, Christian, von Minckwitz, Gunter, Untch, Michael, Pantel, Klaus

“…This study aimed to evaluate the prognostic impact of circulating tumor cells (CTC) detected in patients with operable or locally advanced breast cancer before…”
Get full text

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer by von Minckwitz, Gunter, Eidtmann, Holger, Rezai, Mahdi, Fasching, Peter A, Tesch, Hans, Eggemann, Holm, Schrader, Iris, Kittel, Kornelia, Hanusch, Claus, Kreienberg, Rolf, Solbach, Christine, Gerber, Bernd, Jackisch, Christian, Kunz, Georg, Blohmer, Jens-Uwe, Huober, Jens, Hauschild, Maik, Fehm, Tanja, Müller, Berit Maria, Denkert, Carsten, Loibl, Sibylle, Nekljudova, Valentina, Untch, Michael

“…Bevacizumab added to neoadjuvant combination chemotherapy increased the rate of pathological complete response among patients with HER-2-negative early-stage…”
Get full text

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes by VON MINCKWITZ, Gunter, UNTCH, Michael, JACKISCH, Christian, KAUFMANN, Manfred, KONECNY, Gottfried E, DENKERT, Carsten, NEKLJUDOVA, Valentina, MEHTA, Keyur, LOIBL, Sibylle, BLOHMER, Jens- Uwe, COSTA, Serban D, EIDTMANN, Holger, FASCHING, Peter A, GERBER, Bernd, EIERMANN, Wolfgang, HILFRICH, Jörn, HUOBER, Jens

“…The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Tumor…”
Get full text

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer by Baselga, José, Lewis Phillips, Gail D, Verma, Sunil, Ro, Jungsil, Huober, Jens, Guardino, Alice E, Samant, Meghna K, Olsen, Steve, de Haas, Sanne L, Pegram, Mark D

“…HER2-positive breast cancer is heterogeneous. Some tumors express mutations, like activating PIK3CA mutations or reduced PTEN expression, that negatively…”
Get full text

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 by Hanker, Ariella B, Garrett, Joan T, Estrada, Mónica Valeria, Moore, Preston D, Ericsson, Paula González, Koch, James P, Langley, Emma, Singh, Sharat, Kim, Phillip S, Frampton, Garrett M, Sanford, Eric, Owens, Philip, Becker, Jennifer, Groseclose, M Reid, Castellino, Stephen, Joensuu, Heikki, Huober, Jens, Brase, Jan C, Majjaj, Samira, Brohée, Sylvain, Venet, David, Brown, David, Baselga, José, Piccart, Martine, Sotiriou, Christos, Arteaga, Carlos L

“…Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction…”
Get full text

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial by von Minckwitz, Gunter, Prof, Schneeweiss, Andreas, Prof, Loibl, Sibylle, Prof, Salat, Christoph, MD, Denkert, Carsten, Prof, Rezai, Mahdi, Prof, Blohmer, Jens U, Prof, Jackisch, Christian, Prof, Paepke, Stefan, MD, Gerber, Bernd, Prof, Zahm, Dirk M, MD, Kümmel, Sherko, MD, Eidtmann, Holger, MD, Klare, Peter, MD, Huober, Jens, Prof, Costa, Serban, Prof, Tesch, Hans, Prof, Hanusch, Claus, MD, Hilfrich, Jörn, Prof, Khandan, Fariba, MD, Fasching, Peter A, Prof, Sinn, Bruno V, MD, Engels, Knut, MD, Mehta, Keyur, MBA, Nekljudova, Valentina, PhD, Untch, Michael, Prof

“…Summary Background Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist…”
Get full text

Response-Guided Neoadjuvant Chemotherapy for Breast Cancer by VON MINCKWITZ, Gunter, BLOHMER, Jens Uwe, JACKISCH, Christian, KAUFMANN, Manfred, KÜMMEL, Sherko, PAEPKE, Stefan, SCHNEEWEISS, Andreas, UNTCH, Michael, ZAHM, Dirk Michael, MEHTA, Keyur, LOIBL, Sibylle, DAN COSTA, Serban, DENKERT, Carsten, EIDTMANN, Holger, EIERMANN, Wolfgang, GERBER, Bernd, HANUSCH, Claus, HILFRICH, Jörn, HUOBER, Jens

“…We investigated disease-free survival (DFS) and overall survival (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer. We…”
Get full text

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial by Rothé, Françoise, Silva, Maria Joao, Venet, David, Campbell, Christine, Bradburry, Ian, Rouas, Ghizlane, de Azambuja, Evandro, Maetens, Marion, Fumagalli, Debora, Rodrik-Outmezguine, Vanessa, Di Cosimo, Serena, Rosa, Daniela, Chia, Stephen, Wardley, Andrew, Ueno, Takayuki, Janni, Wolfgang, Huober, Jens, Baselga, Jose, Piccart, Martine, Loi, Sherene, Sotiriou, Christos, Dawson, Sarah-Jane, Ignatiadis, Michail

“…In the neoadjuvant treatment (NAT) setting, dual HER2-targeted therapy is associated with increased pathologic complete response (pCR) rates compared with each…”
Get full text

Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial by RIETHDORF, Sabine, MÜLLER, Volkmar, HILFRICH, Jörn, HOLMS, Frank, TESCH, Hans, EIDTMANN, Holger, UNTCH, Michael, VON MINCKWITZ, Gunter, PANTEL, Klaus, LILING ZHANG, RAU, Thomas, LOIBL, Sibylle, KOMOR, Martina, ROLLER, Marc, HUOBER, Jens, FEHM, Tanja, SCHRADER, Iris

“…This study was aimed at detecting and characterizing circulating tumor cells (CTC) before and after neoadjuvant therapy (NT) in the peripheral blood of…”
Get full text

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial by Untch, Michael, Prof, Loibl, Sibylle, MD, Bischoff, Joachim, MD, Eidtmann, Holger, MD, Kaufmann, Manfred, Prof, Blohmer, Jens-Uwe, Prof, Hilfrich, Jörn, Prof, Strumberg, Dirk, Prof, Fasching, Peter A, Prof, Kreienberg, Rolf, Prof, Tesch, Hans, Prof, Hanusch, Claus, MD, Gerber, Bernd, Prof, Rezai, Mahdi, MD, Jackisch, Christian, Prof, Huober, Jens, Prof, Kühn, Thorsten, Prof, Nekljudova, Valentina, PhD, von Minckwitz, Gunter, Prof

“…Summary Background We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy…”
Get full text

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study by Untch, Michael, Rezai, Mahdi, Loibl, Sibylle, Fasching, Peter A, Huober, Jens, Tesch, Hans, Bauerfeind, Ingo, Hilfrich, Jörn, Eidtmann, Holger, Gerber, Bernd, Hanusch, Claus, Kühn, Thorsten, du Bois, Andreas, Blohmer, Jens-Uwe, Thomssen, Christoph, Dan Costa, Serban, Jackisch, Christian, Kaufmann, Manfred, Mehta, Keyur, von Minckwitz, Gunter

“…PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We…”
Get full text

Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials by Werutsky, Gustavo, Untch, Michael, Hanusch, Claus, Fasching, Peter A., Blohmer, Jens-Uwe, Seiler, Sabine, Denkert, Carsten, Tesch, Hans, Jackisch, Christian, Gerber, Bernd, Schneeweiss, Andreas, Link, Theresa, Krug, David, Huober, Jens, Rhiem, Kerstin, Kühn, Thorsten, Vladimirova, Valentina, Nekljudova, Valentina, Loibl, Sibylle

“…This pooled analysis aimed to evaluate locoregional recurrence (LRR) rates of breast cancer (BC) after neoadjuvant chemotherapy (NACT) and to identify…”
Get full text

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study by Huober, Jens, von Minckwitz, Gunter, Denkert, Carsten, Tesch, Hans, Weiss, Erich, Zahm, Dirk Michael, Belau, Antje, Khandan, Fariba, Hauschild, Maik, Thomssen, Christoph, Högel, Bernhard, Darb-Esfahani, Silvia, Mehta, Keyur, Loibl, Sibylle

“…In order to explore the effect of neoadjuvant chemotherapy (NACT) on clinical mid-course and pathological complete response (pCR) at surgery in different…”
Get full text

Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study by Schulz, Sebastian Viktor Waldemar, Laszlo, Roman, Otto, Stephanie, Prokopchuk, Dmytro, Schumann, Uwe, Ebner, Florian, Huober, Jens, Steinacker, Jürgen Michael

“…Purpose: To evaluate feasibility of an exercise intervention consisting of high-intensity interval endurance and strength training in breast cancer patients…”
Get full text

Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials by Krug, David, Lederer, Bianca, Seither, Fenja, Nekljudova, Valentina, Ataseven, Beyhan, Blohmer, Jens-Uwe, Costa, Serban Dan, Denkert, Carsten, Ditsch, Nina, Gerber, Bernd, Hanusch, Claus, Heil, Joerg, Hilfrich, Jörn, Huober, Jens B., Jackisch, Christian, Kümmel, Sherko, Paepke, Stefan, Schem, Christian, Schneeweiss, Andreas, Untch, Michael, Debus, Jürgen, von Minckwitz, Gunter, Kühn, Thorsten, Loibl, Sibylle

“…Background The impact of locoregional radiotherapy (RT) after neoadjuvant chemotherapy (NACT) and mastectomy in breast cancer patients is currently unclear…”
Get full text

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer by VON MINCKWITZ, Gunter, SCHMITT, Wolfgang D, HILFRICH, Jörn, HUOBER, Jens, FEHM, Tanja, BARINOFF, Jana, RÜDIGER, Thomas, ERBSTOESSER, Erhard, FASCHING, Peter A, KARN, Thomas, MÜLLER, Volkmar, JACKISCH, Christian, LOIBL, Sibylle, DENKERT, Carsten, MÜLLER, Berit M, BLOHMER, Jens U, SINN, Bruno V, EIDTMANN, Holger, EIERMANN, Wolfgang, GERBER, Bernd, TESCH, Hans

“…The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described. Participants of the GeparTrio study with primary…”
Get full text

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups by Johnston, Stephen, O’Shaughnessy, Joyce, Martin, Miguel, Huober, Jens, Toi, Masakazu, Sohn, Joohyuk, André, Valérie A. M., Martin, Holly R., Hardebeck, Molly C., Goetz, Matthew P.

“…In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2−…”
Get full text

Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions by Schochter, Fabienne, Friedl, Thomas W P, deGregorio, Amelie, Krause, Sabrina, Huober, Jens, Rack, Brigitte, Janni, Wolfgang

“…In recent years, breast cancer treatment has become increasingly individualized. Circulating tumor cells (CTCs) have the potential to move personalized…”
Get full text

On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer by Sinn, Bruno Valentin, Sychra, Katharina, Untch, Michael, Karn, Thomas, van Mackelenbergh, Marion, Huober, Jens, Schmitt, Wolfgang, Marmé, Frederik, Schem, Christian, Solbach, Christine, Stickeler, Elmar, Tesch, Hans, Fasching, Peter A, Schneeweiss, Andreas, Müller, Volkmar, Holtschmidt, Johannes, Nekljudova, Valentina, Loibl, Sibylle, Denkert, Carsten

“…Patients with pathologic complete response (pCR) to neoadjuvant chemotherapy for invasive breast cancer (BC) have better outcomes, potentially warranting less…”
Get full text